Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources […]
United Therapeutics is making a major strategic bet on xenotransplantation and bioengineered organs as its primary long-term growth driver. The is using genetically modified pig organs to reduce rejection risk — with its UHeart and UKidney programmes having already achieved transplants in living humans. In parallel, it is developing 3D-bioprinted lungs, livers and kidneys using
A cross-sectional Swiss study involving 124 pulmonary arterial hypertension patients across six centres estimated the annual cost at nearly €139,000 per patient, with direct healthcare costs accounting for 78.5% of this figure — driven predominantly by pharmacological treatment, which alone represented 65% of total costs. Indirect costs, including productivity losses and informal care, made up
Qureight, a data science company, is using synthetic control arms — trial groups generated from existing real-world and historical datasets rather than traditional placebo groups. Their approach involves repeatedly drawing random patient samples from external datasets and matching them to trial participants on key baseline characteristics, generating hundreds of potential control arms. The method has
Pulnovo Medical, a Shanghai-based company developing therapies for pulmonary hypertension and heart failure, has raised $100 million in a strategic financing round led by Medtronic, which has also entered into a separate commercial agreement with the company exploring future commercialisation opportunities. Pulnovo’s flagship product is the Pulmonary Artery Denervation (PADN) System, a minimally invasive device
Within the framework of the PHA 2026 International Conference (June 11-14 in Dallas, Texas), the Global Allergy & Airways Patient Platform (GAAPP) and Latin Health Leaders (LDL) will convene the “Global Pulmonary Hypertension Patient Hackathon“, taking place on June 10 (full day) and June 11 (half day), with the strategic support of the Pulmonary Vascular Research Institute (PVRI) and the Pulmonary Hypertension
The Canadian Pulmonary Hypertension Association (PHA Canada) has launched a “Pulmonary Hypertension Peer Mentor Program”, designed to connect patients and caregivers with trained volunteers. The peer mentors offer a supportive ear, share practical insights, and provide helpful resources based on their own lived experience with pulmonary hypertension. Read more on the PHA Canada website at
The importance of patient-reported outcome measures (PROMs) in assessing health-related QoL has been increasingly recognized, but their implementation remains inconsistent in clinical practice. A systematic review published on April 13, 2026 on Health Quality of Life Outcomes has synthesized the available evidence on the impact of pulmonary arterial hypertension on patients’ QoL measured by PROMs.
GSK has completed the acquisition of 35Pharma, a Canadian clinical-stage biopharmaceutical company. The key asset is HS235, a molecule targeting the activin receptor signalling pathway — the same pathway as sotatercept — designed for the treatment of pulmonary arterial hypertension. HS235 is engineered for greater selectivity than existing agents, with the aim of reducing side
The right heart catheter – also known as cardiac catheterisation, and abbreviated as RHC –is considered the “gold standard’ test to diagnose pulmonary arterial hypertension, and at follow up to monitor progress of the condition and efficacy of treatments. In this video Dr Charlie Elliott, from the Sheffield Pulmonary Vascular Disease Unit, who has performed
The UK Pulmonary Hypertension Association (PHA UK) is inviting everyone in the pulmonary community to enter their Poetry Competition — patients, caregivers, family members, friends, and healthcare professionals alike. It’s free to enter. These are some of the topics suggested: 👉 Visit the PHA UK website to enter.
This month, The Canadian Pulmonary Hypertension Association PHA Canada is raising awareness about the life-changing impact of organ and tissue donation. The newest issue of their magazine Connections is dedicated to Transplant & Pulmonary Hypertension, and it explores this important topic through stories, insights, and resources from the community. 👉 Subscribe to Connections and receive
One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical
Here is a short report: Walk4PH is a growing awareness initiative founded by Ayotunde Omitogun, a pulmonary hypertension patient and founder of the Cardiac Community, a Nigerian non-profit organisation dedicated to improving the lives of people living with heart and lung conditions. This year, Walk4PH has evolved into something larger than a single event. Built
Walk4PH Nigeria: A Community Steps Up for Pulmonary Hypertension Awareness, May 16, 2026 Read Post »
The Canadian Pulmonary Hypertension Association (PHA Canada) has recently announced the setting up of a “Patient Partner Advisory Council (PPAC)”—a new committee which brings together patients and caregivers to help shape the future of the pulmonary hypertension community. The founding members are Angèle Belliveau, Don Downey, Maureen Harper, Brooke Paulin, and Jane Sernoskie. Their lived experience
When science and AI converge: the evolving landscape of Pulmonary Arterial Hypertension (PAH) care Organized by the Alliance for Pulmonary Hypertension Dr. Andreas Reimann: Welcome to this first webinar in a series of four webinars organized by the Alliance for Pulmonary Hypertension this year. I am very happy to welcome you on this Friday evening,
AfPH Q1 2026 WEBINAR FULL TRANSCRIPT Read Post »
With the support of the UK Pulmonary Hypertension Association (PHA UK), trainee psychologist Jacob Pendrey, at Cardiff University in Wales, conducted a study exploring how pulmonary hypertension affects self-image — and the findings are both striking and important. Pulmonary hypertension is known to alter daily life not only through physical limitations, but through profound social
As US Pulmonary Hypertension Association, celebrates its 35th anniversary this year, founders Judy and Ed Simpson reflect on the organization’s history in the latest issue of Pathlight magazine. Check out the timeline at this link The Pulmonary Hypertension Association (PHA) was founded in 1991 by three patients and a nurse in Florida, and has grown
Inhibikase Therapeutics has enrolled the first patient in its global pivotal Phase 3 IMPROVE-PAH trial of IKT-001 for pulmonary arterial hypertension. The trial uses a two-part adaptive design: the first part evaluates change in pulmonary vascular resistance in approximately 140 patients over 12 weeks, followed by a second part focusing on six-minute walk distance in
A descriptive analysis of 54 pulmonary arterial hypertension-related clinical studies registered on international platforms in 2025 was recently published in Pulmonary Therapeutics. The review reveals an evolving and increasingly sophisticated research landscape. Nearly two thirds of the studies were interventional and one third observational, with most involving pharmacological interventions. Most trials involved pharmacological interventions and
